The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed

Beasley C.M. , Tollefson G. , Tran P. , Satterlee W. , Sanger T. , Hamilton S. , and the Olanzapine HGAD Study Group ( 1996) Olanzapine versus placebo and haloperidol — acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123

Dunn C.J. , Fitton A. (1996) Sertindole. CNS Drugs 5: 224-230

Farde L. , Wiesel F-A. , Halldin C. , Sedvall G. (1988) Central D2dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archs Gen Psychiat 45: 71-76

Farde L. , Wiesel F-A. , Nordström A-L. , Sedvall G. (1989) D1- and D2dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: S28-S31

Farde L. , Nordström A-L. , Wiesel F-A. , Pauli S. , Halldin C. , Sedvall G. (1992) Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine—relation to extrapyramidal side effects. Archs Gen Psychiat 49: 538-544

Farde L. , Halldin C. , Lundkvist C. , Ginovart N. , Nyberg S. , Hall H. , Itoh H. , Swahn C. -G, Carr A.A. , Jaquet F. , Brunner F. (1996) [C-11]MDL 100,907, a new PET radioligand for selective imaging of 5-HT2A receptors in the human brain. Eur J Nucl Med 23:1091

Gerlach J. , Casey D.E. (1994) Drug treatment of schizophrenia: myths and realities . Curr Opin Psychiat 7: 65-70

Kane J.M. , Honigfeld G. , Singer J. , Meltzer H. (1988) Clozapine for the treatment-resistant schizophrenic . Archs Gen Psychiat 45: 789-796

Kehne J.H. , Baron B.M. , Carr A.A. , Chaney S. , Elands J. , Fledman D.J. , Frank R.A. , van Giersbergen P L M , McCloskey TC , Johnson M.P. , McCarty DR , Poirot M. , Senyah Y. , Siegel BW , Corinne W. (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmac Exp Therap 277: 968-981

Lader M.H. (1993) Neuroleptic-induced deficit syndrome (NIDS). J Clin Psychiat 54: 493-500

Lundkvist C. , Halldin C. , Ginovart N. , Nyberg S. , Swahn C-G. , Carr A.A. , Brunner F. , Farde L. (1996) [11C]MDL 100,907, a radioligand for selective imaging of 5-HT2A receptors with positron emission tomography. Life Sci 58: PL187-192

Marder S.R. , Meilbach R.C. (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat 151: 825-835

Nordström A-L. , Farde L. , Halldin C. (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110: 365-367

Nordström A-L. , Farde L. , Nyberg S. , Karlsson P. , Halldin C. , Sedvall G. (1995) D1-, D2- and 5-HT2 receptor occupancy in relation to clozapine serum concentration — a PET study in schizophrenic patients. Am J Psychiat 152: 1444-1449

Nyberg S. (1995) PET studies on central receptor binding in relation to clinical pharmacology of antipsychotic drugs. Thesis, Karolinska Institute, Stockholm.

Nyberg S. , Farde L. , Eriksson L. , Halldin C. , Eriksson B. (1993) 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110: 265-272

Nyberg S. , Nordström A-L. , Halldin C. , Farde L. (1995) Positron emission tomography studies on D2 dopamine receptor occupancy and antipsychotic drug plasma levels in man. Int J Clin Psychopharmac 10 (Suppl. 3): 81-85

Nyberg S. , Farde L. , Halldin C. (1996a) A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology, in press

Nyberg S. , Nakashima Y. , Nordström A-L. , Halldin C. , Farde L. (1996b) Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiat 168 (Suppl. 29): 40-44

Peuskens J. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallell-group study versus haloperidol. Br J Psychiat 166: 712-726

Pickar D. , Owen R.R. , Litman R.E. , Konicki E. , Gutierrez R. , Rapaport M.H. (1992) Clinical and biologic response to clozapine in patients with schizophrenia: cross-over comparison with fluphenazine. Archs Gen Psychiat 49: 345-353

Schmidt C.J. , Sorensen S.M. , Kehne J.H. , Carr A.A. , Palfreyman M.G. (1995) The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56: 2209-2222

Schooler N.R. (1994) Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiat Scand 89 (Suppl. 380): 21-26